Sanders-Brown Faculty
| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z |
CONTACT INFORMATION
Room 312, Sanders-Brown Center On Aging
800 South Limestone Street
Lexington, KY 40536-0230
E-MAIL: fascom@email.uky.edu
PHONE: (859) 257-1412 x229
FAX: (859) 323-2866
Frederick Schmitt, Ph.D.
Professor
Departmental Affiliation(s):
Neurology and Sanders-Brown Center on Aging
Research Focus:
Brain-behavior associations in neurological diseases with a focus on (1) early detection of dementia and (2) outcomes of therapeutic interventions in Alzheimer’s disease. Other projects include behavioral and neuroimaging predictors of HIV dementia, Mild Cognitive Impairment, and descriptions of neuropathological changes in brain with advancing age. He has also developed methods for the evaluation of outcomes in the treatment of brain tumors (brain irradiation). Dr. Schmitt participates as an investigator in a number of clinical trials in Alzheimer’s disease and Mild Cognitive Impairment.
Recent Publications:
Bottiggi KA, Chang JJ, Schmitt FA, Avison MJ, Mootoor Y, Nath A, Berger JR. The HIV Dementia Scale: predictive power in mild dementia and HAART. J Neurol Sci 260: 11-15, 2007.
Bottiggi KA, Salazar JC, Yu L, Caban-Holt AM, Ryan M, Schmitt FA. Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. Am J Geriatr Psychiatry 15: 357-359, 2007.
Nelson KR, Mattingly M, Schmitt FA. Out-of-body experience and arousal. Neurology 68: 794-795, 2007.
Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, Abner EL, Markesbery WR. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J Neuropathol Exp Neurol 66: 1136-1146, 2007.
Salazar JC, Schmitt FA, Yu L, Mendiondo MM, Kryscio RJ. Shared random effects analysis of multi-state Markov models: application to a longitudinal study of transitions to dementia. Stat Med 26: 568-580, 2007.
Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68: 1501-1508, 2007.
Schmitt F, Ryan M, Cooper G. A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease. Expert Opin Drug Metab Toxicol 3: 135-141, 2007.
Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Jicha GA, Cooper G, Markesbery WR. Brain structural alterations before mild cognitive impairment. Neurology 68: 1268-1273, 2007.
Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Markesbery WR. Age and gender effects on human brain anatomy: a voxel-based morphometric study in healthy elderly. Neurobiol Aging 28: 1075-1087, 2007.
Weycker D, Taneja C, Edelsberg J, Erder MH, Schmitt FA, Setyawan J, Oster G. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin 23: 1187-1197, 2007.
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F.,
Ferris, S. & Möbius, H.J. (2006). A 24-week open-label extension study of
memantine in moderate to severe Alzheimer’s disease. Archives of
Neurology, 63, 49-54.
Markesbery, W.R., Schmitt, F.A., et
al. (2006). Neuropathological substrate of mild cognitive impairment.
Archives of Neurology,
63, 38-46.
Locke, D.,
Kryscio, R.J.; Schmitt, F.A., et al. (2006). Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology, 66, 828-832.
Nelson, K. Lee, S., Mattingly, M. & Schmitt, F. (2006). Does the arousal
system contribute to near death experience? Neurology, 66,
1003-1009.
Schmitt, F.A. & Wichems, C.H. (2006). A systematic review of assessment and treatment of moderate to severe Alzheimer’s disease,
Journal of Clinical Psychiatry (Primary Care Companion). 8, 158-169.
Feldman HH, Schmitt FA, Olin JT. (2006). Activities of daily living in moderate-to-severe Alzheimer disease: An analysis of the treatment effects of
memantine in patients receiving stable donepezil treatment. Alzheimer Disease and Associated Disorders. 20, 263-268.
Mitchell, DB & Schmitt, FA. (2006). Short- and long-term implicit memory in aging and Alzheimer’s disease. Aging, Neuropsychology, and Cognition, 13, 611-35.
Schmitt FA, van Dyck CH, Wichems CH, Olin JT. (2006). Cognitive Response to Memantine in Moderate to Severe Alzheimer Disease in Patients Already Receiving Donepezil: An Exploratory Reanalysis. Alzheimer Disease and Associated Disorders. 20, 255-262.
Bottiggi KA, Salazar JC, Yu L, Caban-Holt AM, Ryan M,
Mendiondo MS, Schmitt FA. (2006). Long-term cognitive impact of anticholinergic medications in older adults. American Journal of
Geriatric Psychiatry. 14,
980-984.
Hoffmann M, Schmitt F. (2006). Metacognition in stroke: bedside assessment and relation to location, size, and stroke severity. Cognitive and Behavioral Neurology. 19, 85-94.
van Dyck CH, Schmitt FA, Olin JT. (2006). A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. American Journal of Geriatric Psychiatry. 14, 428-37.
Scheff, S, Price, DA,
Schmitt, FA, Mufson, EJ. (2006). Hippocampal
synaptic loss in early Alzheimer’s disease and mild cognitive impairment.
Neurobiology of Aging,
27, 1372-84.
Schmitt, F, Ryan, M, Cooper, G. (2007). A brief review of
the pharmacologic and therapeutic aspects of memantine in Alzheimer’s
disease. Expert Opinion in Drug Metabolism and Toxicology, 3,
135-141.
Salazar, JC, Schmitt, FA, Yu, L,
Nelson KR,
Mattingly M, Schmitt FA. (2007). Out-of-body experience and arousal.
Neurology, 68, 794-795.
Bottiggi KA, Salazar JC, Yu L, Caban-Holt AM, Ryan M, Schmitt FA. (2007). Concomitant use of medications with anticholinergic properties and acetylcholinesterase
inhibitors: impact on cognitive and physical functioning in Alzheimer disease. American Journal Geriatric Psychiatry. 15, 357-359.
Weycker D, Taneja C, Edelsberg J, Erder MH, Schmitt FA, Setyawan J, Oster G. (2007). Cost-effectiveness of memantine in
moderate-to-severe Alzheimer's disease in patients receiving donepezil.
Current Medical Research Opinion. 23, 1187-1197.
Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ.
(2007). Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment.
Neurology,
68, 1501-1508.
Kryscio, R, Schmitt, FA,
Mendiondo, M, & Markesbery, W. (2007).
Hypertension as a risk factor for transitions from normal to dementia or
mild cognitive impairment. Research
and Practice in Alzheimer’s Disease,
12, 139-143.
Dassel KB, Schmitt FA. (2008).
The impact of caregiver executive skills on reports of patient functioning.
Gerontologist.
2008, 48, 781-92.
Hoffmann M, Schmitt F,
Bromley E. (2009). Comprehensive cognitive neurological assessment in
stroke. Acta Neurol Scand. 119,
162-71.
Schmitt, FA, Saxton, JA, Xu, Y, McRae, T, Sun, Y, Richardson, S, Li, H (in press).
A Brief Instrument to Assess Treatment Response in the
Patient with Advanced Alzheimer Disease.
Alzheimer’s Disease Associated
Disorders,
Riesberg, B, Doody, R, Stöffler, A, Schmitt, F,
Ferris, S, & Möbius, H (2003). A randomized, placebo-controlled study of
memantine, an uncompetitive NMDA antagonist, in patients with moderate to
severe Alzheimer’s disease.
Schmitt, F.A., Bigley, J.W., McKinnis,
R., Logue, P., Evans, R., Drucker, J., & AZT Collaborative Working Group.
(1988) Neuropsychological outcome of azidothymidine (AZT) in the
treatment of AIDS and AIDS‑related complex: A double‑blind,
placebo‑controlled trial.
Book Chapters:
Schmitt, F.A., Ranseen, J.D., & DeKosky, S.T. (1989)
Cognitive mental status examinations. In: F.J. Pirozzolo (ed.),
Clinics in Geriatric Medicine: New developments in neuropsychological
evaluation. W.B. Saunders Company, pp 545-564.
Schmitt, F.A., & Ranseen, J.D. (1989)
Neuropsychological assessment of older adults. In: T. Hunt & C. J.
Lindley (eds.) Testing older adults: A reference guide for
geropsychological assessments.
Schmitt, F.A., & Ranseen, J.D. (1991)
Neuropsychological toxicology and aging. In: R.L. Cooper, J.M.
Goldman, & T.J.
Schmitt, F.A., Bigley, J.W., & AZT Collaborative Group
(1991). HIV-associated cognitive impairment: Response to
zidovudine. In: G. Racagni, N. Brunello, & T. Fukuda (Eds.),
Biological Psychiatry (Vol. 2), Excerpta Medica, Elsevier Science
Publishers:
Schmitt, F.A., Honeycutt, N., & VanGorp, W. (1992)
Neuropsychologic aspects of HIV Infection.
Reviews
(Vol. 6), Mills Press, pp. 513-529.
Schmitt, F. & Sano, M. (1994)
Neuropsychological approaches to the study of dementia. In: J.C. Morris (ed.), Handbook of Dementing
Illnesses. Marcel Dekker, Inc., pp 89-124.
Schmitt, F.A., Dickson, L., & Brouwers, P. (1994)
Neuropsychological outcomes of treatment of HIV infection. In:
Brouwers, P., Wolters, P., Moss, H., & Schmitt, F.
(1994) Neuropsychological aspects of pediatric HIV infection.
In:
Schmitt, F.A., Wetherby,
M., & Stern, Y.
(1996) Neuropsychological aspects of HIV
infection. In: R. Levy & J. Berger (eds.) AIDS and
the nervous system. Raven Press.
Schmitt, F.A., et al. (1997) Severe Impairment
Battery: A potential measure for Alzheimer’s disease clinical trials.
In: R. Becker & E. Giacobini (Eds.) Alzheimer disease: From molecular
biology to therapy.
Wetherby, M., Cheong, J., Evans, D., & Schmitt, F. (1998)
Pharmacological interventions for neuropsychiatric Symptoms of HIV disease.
In: W. VanGorp & S. Buckingham (eds.) Practitioner’s guide to
the Neuropsychiatry of HIV/AIDS.
Caban-Holt, A., Mattingly, M.,
Cooper, G, & Schmitt, F.A. (2005) Neurotoxicology and dementia.
Neurology Clinics
Cooper, G.E. and Schmitt, F.A. (2005) A “Field Guide” to
Mental Status Testing. Practical Neurology, 4, 68-73.